PFE News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PF

Mkt Cap

$158.56B

Volume

19.11M

Next Earnings

November 3rd

Chart Financials Earnings News About Dividends Insider Filings

Top Research Reports for JPMorgan, ASML & ChevronZacks Research Daily features analysis of 16 major stocks including JPMorgan Chase, ASML, and Chevron, plus two microcap stocks. JPMorgan benefits from strong earnings and diversified revenues; ASML faces balanced opportunities and risks from AI demand; Chevron shows strong production growth and cash flow. Additional coverage includes Pfizer, Valero Energy, and Constellation Energy, with mixed outlooks across sectors.Zacks Investment Research · Oct 9, 2026

Cancer Stocks to Consider as Oncology Innovation AcceleratesThe global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories.Zacks Investment Research · Oct 9, 2026

Roche Gets FDA Approval for Another Label Expansion of TecentriqRoche received FDA approval for Tecentriq in combination with chemotherapy for adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The phase III ATOMIC study demonstrated a 50% reduction in recurrence or death risk, with 86% disease-free survival at 36 months versus 76% for chemotherapy alone. This marks Tecentriq's 12th U.S. indication and positions it as the first approved adjuvant immunotherapy for this cancer type.Zacks Investment Research · Oct 9, 2026

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to KnowPfizer has been heavily searched on Zacks.com lately. The stock returned +0.6% over the past month, underperforming the S&P 500's +1.3% gain. Pfizer holds a Zacks Rank #2 (Buy) rating based on earnings estimate revisions and other factors. The company is expected to report declining earnings year-over-year but has consistently beaten consensus estimates in recent quarters. Pfizer trades at a valuation discount to peers with a B grade on the Value Style Score.Zacks Investment Research · Oct 9, 2026

Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive GrowthThe global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.GlobeNewswire Inc. · Oct 9, 2026

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.The Motley Fool · Oct 9, 2026

NVS Wins FDA Nod for Label Expansion of Immunology Drug RhapsidoNovartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs.Zacks Investment Research · Oct 8, 2026

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?Pfizer (PFE) is highlighted as a stock well-positioned to continue beating earnings estimates in its upcoming report on November 3, 2026. The company has surpassed consensus estimates by an average of 9.43% in the last two quarters and currently has a positive Earnings ESP of +12.30% combined with a Zacks Rank #2 (Buy) rating, suggesting a high probability of another earnings beat.Zacks Investment Research · Oct 8, 2026

Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsPfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 8, 2026

FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerPfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option.Zacks Investment Research · Oct 8, 2026

PF

PFEPfizer Inc.

PFE

Pay with—

Available Balance0.00

Your PositionYou don't own any PFE yet.

Related Tickers

Earnings

Dividends

Ex Nov 6

Amount$0.43

PaysDec 7

Last · Jul 24Quarterly

Amount$0.43

Yield6.08%

Annual$1.72